Outcomes in Patients with Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 503-510

  Poppe, Katrina K ^a   Doughty, Robert N ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Heart failure; Preserved ejection fraction; Reduced ejection fraction

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; RENIN INHIBITOR; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CAUSE OF DEATH; COMORBIDITY; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; AGED; CARDIAC OUTPUT, LOW; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; SYNDROME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; CAUSE OF DEATH; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT READMISSION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL RATE; SYNDROME; TREATMENT OUTCOME;

EID: 84903398654     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.012     Document Type: Review

References (47)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Blackledge H.M., Tomlinson J., Squire I.B. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 2003, 89:615-620.
3. Schaufelberger M., Swedberg K., Köster M., et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish hospital discharge registry 1988 to 2000. Eur Heart J 2004, 25:300-307.
4. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
5. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
6. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352:225-237.
7. Maeder M., Kaye D. Heart failure with normal left ventricular ejection fraction. JAm Coll Cardiol 2009, 53:905-918.
8. Cleland J.G., Tendera M., Adamus J., et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999, 1:211-217.
9. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
10. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003, 362:777-781.
11. Steinberg B.A., Zhao X., Heidenreich P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012, 126:65-75.
12. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355:260-269.
13. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
14. Jhund P.S., MacIntyre K., Simpson C.R., et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009, 119:515-523.
15. Shafazand M., Schaufelberger M., Lappas G., et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish hospital discharge registry. Eur Heart J 2009, 30:671-678.
16. Hall M.J., Levant S., DeFrances C.J. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief 2012, 108:1-8.
17. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. JAm Coll Cardiol 2006, 47:76-84.
18. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. JAm Coll Cardiol 2007, 50:768-777.
19. Somaratne J.B., Berry C., McMurray J.J., et al. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail 2009, 11:855-862.
20. Meta-analysis Global Group in Chronic Heart Failure Investigators (MAGGIC) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012, 33:1750-1757.
21. Burkhoff D. Mortality in heart failure with preserved ejection fraction: an unacceptably high rate. Eur Heart J 2012, 33:1718-1720.
22. Padwal R., McAlister F.A., McMurray J.J., et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes 2013, 10.1038/ijo.2013.203.
23. Rusinaru D., Tribouilloy C., Berry C., et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Eur J Heart Fail 2012, 14:1139-1146.
24. Martinez-Selles M., Doughty R.N., Poppe K., et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail 2012, 14:473-479.
25. McAlister F.A., Ezekowitz J., Tarantini L., et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012, 5:309-314.
26. Pocock S.J., Ariti C.A., McMurray J.J., et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013, 34:1404-1413.
27. Sartipy U., Dahlström U., Edner M., et al. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2014, 16:173-179.
28. Poppe K.K., Squire I.B., Whalley G.A., et al. Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. Eur J Heart Fail 2013, 15:1220-1227.
29. Campbell R.T., Jhund P.S., Castagno D., et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. JAm Coll Cardiol 2012, 60:2349-2356.
30. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121:1393-1405.
31. Solomon S.D., Wang D., Finn P., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004, 110:2180-2183.
32. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112:3738-3744.
33. Henkel D., Redfield M.M., Weston S., et al. Death in heart failure: a community perspective. Circ Heart Fail 2008, 1:91-97.
34. Grigorian-Shamagian L., Raviña F.O., Assi E.A., et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of>600 deaths in a community long-term study. Am Heart J 2008, 156:1184-1190.
35. Doughty R., Yee T., Sharpe N., et al. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. NZ Med J 1995, 108:473-475.
36. Rydén-Bergsten T., Andersson F. The health care costs of heart failure in Sweden. JIntern Med 1999, 246:275-284.
37. Stewart S., Jenkins A., Buchan S., et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002, 4:361-371.
38. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116:1482-1487.
39. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
40. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
41. Shah R.V., Desai A.S., Givertz M.M. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. JCard Fail 2010, 16:260-267.
42. van Veldhuisen D.J., McMurray J.J. Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?. Eur J Heart Fail 2013, 15:5-8.
43. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348:1309-1321.
44. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEngl J Med 1999, 341:709-717.
45. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
46. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
47. Shah S.J., Heitner J.F., Sweitzer N.K., et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013, 6:184-192.